Randomized trial · people
Amycretin: HbA1c fell up to 1.7% at 36 weeks in type 2 diabetes
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In adults with type 2 diabetes, every amycretin dose tested from 0.4 to 40 mg lowered HbA1c more than placebo over 36 weeks, and the side effects were mostly gut-related.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 262
- Published
- 2026
- Journal
- Lancet
What they tested
The team tested how different weekly doses of amycretin (now called zenagamtide), injected under the skin, changed blood sugar control and safety compared with placebo in adults with type 2 diabetes.
How the study was done
A randomized, double-blind, placebo-controlled phase 2 trial that enrolled 262 adults with type 2 diabetes at 83 sites in 11 countries; everyone was on a steady metformin dose, and some also used an SGLT2 inhibitor. For 36 weeks, each person got one of six weekly doses (0.4, 1.5, 5, 10, 20 or 40 mg) or placebo (a dummy shot), starting at 0.2 mg and stepping up every 4 weeks.

What they found
Average HbA1c (a 3-month average of blood sugar) was 7.8% at the start. By week 36, it fell by 0.9% in the 0.4 mg arm, a difference of -0.77% versus placebo (95% CI -1.26 to -0.28), and by 1.7% in the 40 mg arm, a difference of -1.56% versus placebo (95% CI -2.05 to -1.07). Most side effects involved the gut and were mild to moderate. Serious adverse events occurred in 21 (8%) of 261 treated participants, 3 of them on placebo, and no one died.
What it doesn’t show
This was a 36-week dose-finding trial with a small placebo group of 37 people, all of them adults with type 2 diabetes on background metformin. It was funded by Novo Nordisk.
The paper
Mora et al. Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. Lancet. 2026.
The compound
More studies on Amycretin
- Amycretin: oral 50 mg arm cut HbA1c by 1.4% at 36 weeksRandomized trial · people · 2026
- Amycretin: 24.3% weight loss at 36 weeks in a phase 1b/2a trialRandomized trial · people · 2025
- Amycretin: side effects all mild or moderate in first human trialRandomized trial · people · 2025
- Amycretin: similar drug exposure with kidney impairment in phase 1Clinical trial · people · 2026
- Amycretin cut body weight by 18% in obese rats over 21 daysAnimal study · mice and rats · 2025
- Every study on Amycretin
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.